What are some of the problems with nucleoside therapy? The nucleoside analogs that have been marketed are Herceptin (lamivudine), Haverix (adefovir), Boludin (entecavir), and Sulbivir (telbivudine). Because these drugs are strong inhibitors of viral replication, they quickly relieve liver inflammation and most patients have normal liver function tests within a few months. The vast majority of patients will relapse after discontinuation of these drugs, and relapse after discontinuation may be catastrophic in a minority of patients. There is a greater risk of acute exacerbation of the disease after discontinuation of Haverix, so long-term maintenance therapy is usually required. Another problem with this class of drugs is that long-term treatment with one drug can lead to drug-resistant mutations, especially with Herceptin, which has an annual incidence of 20%, and when resistance occurs the virus and serum transaminase levels rebound, which can also be catastrophic. In the past, there was only one nucleoside analog, and long-term treatment was required. Tens of thousands of patients have already developed heptyn resistance, and now, although there are four nucleoside analogs, patients who are resistant to heptyn may be cross-resistant, which will at least reduce the susceptibility of the virus to new drugs and make treatment a lot more difficult. The thing that worries us now is that patients do not use the drugs regularly. Because there are few adverse reactions to these drugs, they are easy and safe to take, and many patients use them like painkillers or stomach medicine, stopping them at will, using them when their serum transaminases are elevated and stopping them when they are normal. The pharmaceutical market is not strictly managed, and patients can buy these drugs in pharmacies without prescription. What are some problems with interferon therapy? Interferon treatment for chronic hepatitis B has a high rate of transfer to the team of “major triplets”, and the conversion to “minor triplets” can continue to inhibit viral replication after discontinuation of the drug, resulting in sustained remission of inflammation, fewer relapses, and a fairly stable antiviral effect. The antiviral effect is quite stable, and some patients with effective treatment may be cured within a few years by clearing “small triplets”. The long-term goal of interferon therapy is to prevent the progression to cirrhosis and hepatocellular carcinoma, and this effect has been confirmed by some long-term follow-up reports. However, there are some adverse effects with interferon, and there are many variables in the treatment process, so it is of course much more difficult to deal with such patients. Interferon only cures about half of the patients, and doctors are often apprehensive about treating patients who are not well. Treatment with interferon requires some experience. If you’re looking for a new way to get the most out of your life, you’ll be able to get the most out of your life. The current situation of chronic hepatitis B treatment is the application of antiviral drugs is too little, including the application of interferon treatment is even less, can use and dare to use interferon is mainly some large urban hospitals, can actively use interferon, for patients to fight for a better treatment effect only part of the specialist doctors.